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Abstract 
Introduction: During cancer treatment the timely detection and management of 
adverse events (AE) is essential for patient safety and maintaining quality of life. 
eRAPID was devised to support oncology practice, by allowing patients to self-report 
symptoms online at home during and beyond cancer treatment. Fundamentally the 
eRAPID intervention delivers immediate severity-tailored feedback directly to patients 
to guide self-management strategies or hospital contact. Patient data are available in 
electronic health records (EHR) for hospital staff to access and review as part of 
clinical assessments.  
Methods for interpreting and addressing PRO scores: The eRAPID intervention 
has 5 main interconnecting components (clinical integration into standard care 
pathways, patient symptom reports, self-management advice, information technology 
and staff/patient training). Following guidance for the development of complex 
interventions and using a mixed methods approach, eRAPID was created through a 
number of stages and tested in a series of usability settings before undergoing 
systematic evaluation in an ongoing randomised controlled trial.  These developmental 
stages are described here with a focus on how decisions were made to enhance 
patient and professional engagement with symptom reports and encourage 
interpretation and clinical utilisation of the data.  
Discussion: Clinically embedded PRO interventions involve a number of elements 
and stakeholders with different requirements. Following extensive developmental work 
eRAPID was pragmatically designed to fit into current oncology practices for reviewing 
and managing chemotherapy-related toxicities. 
Key Take-Home Points:  Co-design with patient and professional stakeholders is 
vital. The adoption of a flexible and experiential approach is recommended. 
4 
 
Transparent use of PRO data is important to encourage ongoing patient and 
professional engagement with the intervention.  
 
Key words: Patient Reported Outcomes (PROs); cancer; chemotherapy; online 
intervention; adverse events 
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Introduction 
The toxic nature of many cancer therapies puts patients at risk of a diverse range of 
side effects from mild complications to potentially life threatening adverse events 
(AE).1-3  Robust and comprehensive practices for monitoring patients are essential for 
the safe and successful delivery of treatment regimens and to optimise patient 
functioning and well-being. The task of assessing and recording AEs has traditionally 
been the responsibility of the treating clinical team. However, treatment toxicities are 
typically not well captured or conveniently accessible within medical records. In 
addition, with most therapeutic agents being administered in an outpatients setting, 
patients are largely responsible for monitoring their own symptoms when away from 
the hospital environment. Patients report challenges with understanding the clinical 
severity of particular symptoms and the appropriate options for self-management or 
clinical care.4 In response to these challenges eRAPID was devised to allow online 
patient reporting during cancer treatment. Using eRAPID patients can report 
symptoms and side effects from home and patient data is available for oncology staff 
to access and utilise in clinical assessments with a central focus of the system being 
the provision of immediate severity-tailored patient feedback (based on PRO scores) 
to support self-management strategies or guide when hospital contact should be 
sought. Patient data are also accessible in electronic health records (EHR) for clinical 
staff to review and staff can also be emailed notification of severe symptoms.  
 
Our aim with eRAPID was to encourage the delivery of timely and appropriate patient-
centred clinical advice during cancer treatment to improve the management of adverse 
events. The overall research programme has three separate strands focussing on the 
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delivery of the intervention in systemic chemotherapy, radiotherapy5 and surgical 
settings6 within cancer services in the National Health Service (NHS) in the UK. 
A large single-centre randomised controlled trial (RCT) has been conducted to 
evaluate eRAPID with patients undergoing systemic cancer treatment7, results of 
which will be available in summer 2019.7 The main trial explores the potential 
benefit of the intervention on patient quality of life, and process of care outcomes 
(including number of emergency and hospital admissions and associated health 
economic implications). In addition patients and staff are being interviewed and asked 
to provide written feedback about their perceptions of how eRAPID has worked in 
practice and its impact on care.  
 
From the outset of the eRAPID programme we recognised there were a range of 
important elements and challenges to the design and clinical integration of the system 
in order for the patient reported symptom data to lead to improved clinical 
management and patient outcomes. It was a primary goal that eRAPID should 
enhance current practice at the local cancer centre and be a valuable addition to 
clinical assessments performed by oncology staff. Here we provide an overview of the 
eRAPID developmental and usability work focussing on how the system was created 
in order to maximise how clinical staff and patients engage with, interpret and act upon 
the patient reported data.  
 
Methods:  
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eRAPID can be divided into 5 main complementary components, all of which are 
integral for optimising the intervention and encouraging patient and professional 
interpretation and utilisation of PRO data.  
1. Clinical integration of eRAPID: Documentation of routine oncology care 
pathways and workflows to optimise placement of a PRO intervention 
2. Patient symptom reports: Use of clinically appropriate items complying with 
standard medical assessments of symptom toxicity  
3. Severity tailored self-management advice: Delivery of timely and accurate 
advice to support patient management of mild, moderate and severe AE  
4. Information technology: Use of robust and secure systems for capturing 
patient data, delivering self-management advice and making data accessible to 
clinical teams in electronic patient records  
5. User training: The provision of flexible and sustainable patient and staff 
training to support the adoption and ongoing acceptance of the intervention 
The development and evolution of these elements was directed by the Medical 
5HVHDUFK &RXQFLO¶V complex intervention guidance.8 Mixed methods have been 
adopted throughout all stages. At the heart this has been a co-design approach with 
the end-users of the system, both health professionals and patients to maximise the 
relevance and practical application of PRO data. From project conception 
oncologists, nursing and hospital informatics leads at the local cancer centre 
were involved in the proposal as co-applicants and as workgroup members 
once funding was awarded. Below we describe in more detail the methods used to 
address each of the elements underpinning eRAPID and provide a case study 
demonstrating how the intervention has worked to guide patient care in practice. We 
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highlight the main learning points derived to date for supporting eRAPID PRO 
interpretation and subsequent actions in this systemic cancer setting.  
 
1. Clinical integration of eRAPID 
Preliminary work focussed on understanding the clinical need for the eRAPID PRO 
intervention and mapping current oncology care pathways and workflows to ascertain 
where the system can be best be placed to support patient care. The local NHS 
cancer hospital (Leeds Cancer Centre, Leeds, UK) had reorganised the acute 
oncology service in 2010 to include a dedicated acute admissions ward and 
assessment unit. A nurse-led telephone triage system was adopted and patients 
receiving anti-cancer therapy are given an emergency contact number to call for AE 
related problems. A clinical audit was conducted to evaluate and understand this new 
service.4 Data were collected in 2011 and again in 2013 to determine how the triage 
processes were being assimilated by assessing the integrity of triage data being 
routinely collected, a summary of AE issues patients were seeking help for and the 
clinical advice or management provided. In addition a subset of patients admitted to 
the acute admissions ward were interviewed about their understanding of AE and 
routes to admission. We also worked with clinical teams to map the standard pathways 
through which patients typically pass during their treatment and the staff involved with 
the routine treatment reviews. We conducted 12 interviews with staff involved in the 
delivery of chemotherapy pathways, exploring organisational issues and clinical 
decision making processes in relation to symptoms triggering admission and 
GHWHUPLQHGWKHSDWLHQW¶VSRints of contact during and out-of-office hours.  
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There were a number of valuable learning points ascertained through this exercise. 
Importantly we discovered a significant proportion of the acute contacts were with 
breast, gastrointestinal and gynaecological patients; patients admitted during 
treatment frequently reported experiencing symptoms for a number of days before 
contacting the service and a considerable number of calls were for non-emergency 
problems.  
 
We learned about pathway variation across the different cancer groups which 
highlighted the main health care professionals involved in clinical assessments. We 
discovered that in some pathways the clinical nurse specialists played a significant 
role in assessing patients. In other groups the oncologists were delivering more of the 
chemotherapy review consultations. Valuable insight into the main patient groups 
seeking acute oncology support guided the initial plan to design the intervention for 
use with breast, gynaecological and colorectal cancer patients. The common issues 
patients presented with to acute oncology services highlighted the range of support 
needs, demonstrating where and when patients could be encouraged to contact the 
hospital and how help for less medically concerning problems may be delivered with 
online informational support.  
 
2. Patient symptom reports 
The selection and development of items for patient self-report began with a review of 
the main systemic treatments prescribed for breast, colorectal and gynaecological 
cancers. Associated AE information was gathered via a) a literature review of AEs 
reported in clinical trials b) analysis of patient-reported symptoms collected from our 
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previous studies in Leeds c) collation of the symptoms recorded in the acute triage 
assessments (as described above).  
 
A core set of AEs were identified including nausea, vomiting, diarrhoea, mucositis, 
fatigue, insomnia, palmar-plantar erythema, pain, peripheral neuropathy, appetite 
loss, constipation, rash, bleeding, anaemia, febrile neutropaenia and stoma problems. 
Clinical and nursing representatives from each tumour group provided input on the 
most clinically important AE for reviewing their patient group during treatment. The 
professionals also added physical activity/ performance status to the list of symptoms.  
 
Working in line with the standard assessment procedures used by the oncology teams, 
we adopted the Common Terminology Criteria for Adverse Events (CTCAE) to guide 
the development of the patient reported AE items and ensure compatibility with current 
practice. The US National Cancer Institute's Patient-Reported Outcomes Version of 
the Common Terminology Criteria for Adverse Events (PRO-CTCAE)9  were not fully 
validated at the time consequently a set of Patient Reported Adverse Event (PRAE) 
items were locally devised by converting the CTCAE descriptors into a patient friendly 
format with response options aligned to the standard severity grading (see Figure 1).10 
PRAE items were then presented to representatives from the care teams to determine 
the core clinically relevant items to be included in the eRAPID symptom report for each 
cancer group. Decisions were made with the clinical teams on the assignment of 
clinically significant symptom items and severity grades and an underlying algorithm 
was devised to determine the scoring of symptom reports and the level of advice 
generated (see Table 1). Following system testing in the breast service11 an important 
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modification was made to the symptom report to accommodate patients reporting 
severe symptoms that may have already been resolved (questions ask about the last 
7 days). An additional branching question was included to confirm current status and 
prevent unnecessary severe symptom notifications. 
 
3. Severity tailored self-management advice  
As mentioned above, a fundamental aspect of the eRAPID intervention is the delivery 
of immediate tailored feedback advice directly to patients to encourage appropriate 
and timely action. Advice was collated from a number of sources including national 
patient and clinical guidance documents resources and reputable cancer websites. 
We liaised closely with clinical staff and hospital information specialists. Due to the 
wealth of available information, advice for each symptom was developed for two 
formats 1) as a succinct summary to be presented immediately after online patient 
symptom reports were completed and 2) the eRAPID website where all the advice and 
wider information was collated. The website was structured around three themes 
µ0DQDJLQJWUHDWPHQWV\PSWRPVDQGVLGHHIIHFWV¶µKeeping healthy during cancer¶DQG
µCoping with cancer and your treatment¶ Usability testing of the self-management 
advice and website was initially conducted with members of our local patient Research 
Advisory Group to ensure advice matched that provided by oncology staff.12 
 
4. Information technology 
The eRAPID system comprises a number of IT elements including a password 
protected patient facing website, a web-based questionnaire builder and a web 
applications interface for securely transferring and displaying PRO data within the local 
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EHR.13 This is an example of a µhybrid¶ system where a stand-alone PRO collection 
facility interfaces with an existing EHR through moderate levels of integration 14. 
 
The eRAPID research team worked with a private software company (XLab 15) to add 
the necessary functionality to QTool (an existing questionnaire management 
system).16 Additions to QTool included enhancing the item scoring dependency 
function to implement the clinical algorithms described above to allow feedback of the 
tailored self-management advice (including a hyperlink capability leading patients to 
the eRAPID information website). Features to provide the option of reviewing previous 
responses and advice in written and graphical formats as well as printing and emailing 
advice were added to allow for practical patient engagement with data. Again, clinical 
and patient representatives played an integral role in usability testing of the online 
symptom reports in QTool providing feedback on system navigation and the user 
interface. 12, 13 
 
Making PRO data available from the local cancer centre¶V EHR was a prime objective 
of eRAPID. To encourage professional engagement with the patient reports we 
wanted the data to be easily accessed alongside the clinical information used during 
patient reviews. Fundamentally the eRAPID programme grant funded the role of 
an Informatics Manager who was able to focus exclusively on making this 
possible. The Informatics Manager worked closely with the hospital EHR 
development team (the cancer centre utilises a bespoke in-house EHR called 
Patient Pathway Manager, PPM) and the X-Lab software developers. The 
research team and a wider stakeholder group of clinicians and patients also 
13 
 
provided valuable feedback and usability testing.13 A web application was created 
allowing the data flow of anonymised reports from QTool to be linked to individual 
patients and viewed in the local EHR. A separate tab in the patient EHR view was 
created so staff could move between medical data and symptom reports for an 
individual patient. The default view is a graphical depiction of each symptom severity 
level (1 = mild 2= moderate 3= severe) over time (see Figure 2 for example EHR 
screenshot). The display can be modified by the user to show data over different time 
periods. Results can also be viewed in a table alongside any free text items provided 
by the patient. Following staff feedback during a usability testing in the breast clinic, 
graphs were revised to include chemotherapy delivery dates to help guide 
interpretation of symptom trajectories. The option for a notification element was also 
added to QTool allowing health professionals to be emailed if clinically severe 
symptoms were reported. A report can be accessed in the EHR which summarises 
when the symptom was reported and by which patient. Although the notifications are 
in place in the ongoing RCT (with emails sent to selected key health professionals for 
each cancer group, e.g. gynaecology specialist nursing teams) an immediate 
response cannot be guaranteed therefore participating patients are aware of their 
responsibility to contact the hospital as needed and do not expect to be directly 
contacted by medical teams. 
 
5. User training 
The training of the key stakeholders in using a new PRO system is a fundamental 
aspect to intervention success. In the ongoing eRAPID evaluation studies the research 
team deliver face-to-face sessions with individual patients where the system is 
demonstrated and log in details and user manuals (developed with input from patient 
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representatives) are provided for supporting patients outside of the hospital setting. 
Staff training sessions have taken a number of forms. Initially, group sessions were 
arranged with all clinical staff (oncologists, specialist nurses and pre-assessment 
nursing teams) with responsibility for conducting routine chemotherapy review 
assessments with gynaecology, colorectal and breast patients. Training covered the 
background to eRAPID and provided practical demonstrations of locating the data in 
the EHR and the patient interface. In addition ad hoc one-to-one sessions have been 
required for individual new staff joining services. During eRAPID usability phases we 
observed a number of consultations to see how staff engaged with the data and 
incorporated it into clinical encounters and obtained feedback from staff on how they 
used PRO data in consultations.11 We found there was a tendency for professionals 
to review data but not overtly refer to it. Subsequently, patients were unsure if their 
data were being used. Staff commented that data was more useful when patients had 
provided regular symptom reports over time. This reciprocal relationship between 
patients and staff both explicitly recognising the value of PRO data is likely to be 
important for maintaining engagement from both parties. eRAPID training now 
includes encouragement to professionals to acknowledge the PROs and for patients 
to mention they have data available to review. As the eRAPID systemic RCT has 
progressed it is apparent that the constraints of the controlled trial leads to staff only 
seeing a small number of patients every week with PRO data. Thus they can forget 
these data are available and limits opportunities to practice utilising patient reports. In 
a bid to create a sustainable approach to staff training in time pressured clinical 
settings and involve interactive elements (which we previously found to be useful in 
earlier studies 17) we recently created an e-learning package accessed from a 
15 
 
hyperlink in the EHR which includes background information and clinical scenarios 
using example eRAPID PRO data. 
 
eRAPID case study 
Figure 2 summarises a case study from the ongoing eRAPID RCT of the experience 
of a patient with early breast cancer. In this instance the eRAPID symptom report and 
immediate patient advice supported an early diagnosis of metastatic disease. 
 
Discussion 
The successful monitoring and management of patients¶ physical symptoms and wider 
psychological well-being during cancer treatment is extremely important. With many 
patients being outside of the hospital when problems occur interventions that utilise 
online technology appear well-placed to help support patient care. A number of other 
electronic symptom reporting interventions in cancer settings have been developed 18-
21
 and there is a growing body of evidence supporting their clinical value. eRAPID is 
unique in that 1) a central function of the system is the delivery of immediate feedback 
for guiding patients to take an appropriate level of action for reported symptoms and 
2) PRO data is directly accessible to health professionals from within the local hospital 
electronic system.  
 
We have taken an experiential and pragmatic approach. Fundamentally we aimed to 
develop a PRO intervention that complemented the symptom monitoring strategies 
and the CTCAE grading systems already in place in routine care to enhance the 
likelihood of professional engagement. From our developmental and usability phases 
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(described in more detail elsewhere10, 11, 13) invaluable lessons were learned through 
patient and staff feedback about the design and content of the symptom reports, the 
scoring algorithms/self-management advice and the display of PRO data in the 
electronic health records. This led to a number of important refinements to the 
intervention before the RCT began and endorses the benefit of embracing a co-design 
approach with patient and professionals being equally recognised as active and 
integral stakeholders. It is important to also note that practical aspects of the 
development work described here took place over a 4 year period and were 
conducted by a team of researchers (including research fellows, research 
assistants, research nurses and the Informatics Manager). Although much of 
what has been learned here (and from other teams) can be used to help support 
future application of similar PRO systems, staff resources are still required to 
establish and refine the integration of electronic PROs into clinical settings. As 
part of the eRAPID programme the IT system was established at two other 
hospitals in the UK for the radiotherapy5 and surgical6 work streams. This 
uncovered a variety of challenges and our team is currently exploring options 
to refine and streamline the process of PRO integration across different EHRs. 
 
Results from the eRAPID systemic RCT will be available in summer 2019. 
Anecdotally we can acknowledge that the randomised controlled trial methodology 
creates restrictions. Staff see a limited number of patients with eRAPID symptom 
reports, therefore engagement with the PRO data is not currently second nature. 
Training is important but if professionals only see a narrow patient group with PRO 
data then this element can lose impact. In the future broader implementation of the 
intervention into standard care would be beneficial to help staff hone use of PRO data. 
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This in turn would likely lead to positive implications for patient engagement if staff are 
seen commonly using data in practice.  
 
With many health services under pressure to meet the needs of growing and ageing 
patient populations, strategies to support effective self-management continues to 
receive particular attention. More PRO interventions that support both patient and 
health professionals in clinical assessment and management are warranted. It is 
important we understand the elements that help keep patients engaged with personal 
symptom monitoring and support confidence in electronically based systems. As 
moves to develop robust clinically integrated technology for collecting and utilising 
patient reported data becomes commonplace it is important that experiences of 
developing and optimising the implementation of these systems be shared and a 
knowledge base generated to help guide expansion and utilisation moving forward. 
 
Key take home points 
x Clinically integrated PRO interventions are complex with a combination of 
overlapping elements.  
x Patients and clinical staff can require different features and functions to 
encourage successful interpretation and use of the data. A co-design 
approach to optimise processes for effectively using PRO data is essential. 
x Patients and health care professionals should be advised to actively 
acknowledge patient reported data in clinical encounters to encourage 
sustained engagement with the PRO interventions. 
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x Electronic PRO systems must be flexible and adaptable to changing user 
needs, emerging new treatments and technological advances. 
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Figure and table legends 
Figure 1: Example of Common Terminology Criteria for Adverse Event (CTCAE) and 
patient self-reporting item for oral mucositis 
Figure 2: eRAPID case study 
Table 1. Overview of scoring algorithm for symptom report and immediate patient 
advice 
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Figure 1: Example of Common Terminology Criteria for Adverse Event 
(CTCAE) and patient self-reporting item for oral mucositis 
 
 
 
CTCAE item 
Definition: A Disorder 
characterised by 
inflammation of the oral 
mucosal. 
Attributes: Severity, 
Interference 
Patient reported adverse event (PRAE) item 
and advice 
Have you had a sore mouth or tongue? 
 
 
Grade 
1. 
Asymptomatic or 
mild symptoms; 
intervention not 
indicated 
 
My mouth was a 
bit sore 
Self- management advice: 
x Background 
information- why the 
mouth can be 
affected during 
cancer treatment 
x General good 
practices for helping 
mouth care during 
cancer treatment 
x Medications- advice 
on prescribed 
mouthwashes and 
when to use them and 
the availability of over 
the counter products 
x Types of drinks and 
food products that 
may be suitable to try 
and those to avoid 
Grade 
2. 
Moderate pain; 
not interfering 
with oral intake; 
modified diet 
indicated 
 
My mouth was 
quite sore but I 
was still able to 
drink and eat 
soft foods 
Grade 
3. 
Severe pain; 
interfering with 
oral intake 
 
My mouth was 
very sore and I 
was not able to 
eat or drink 
You have indicated a 
serious problem in this 
area. We recommend that 
you contact the hospital 
now to discuss your 
symptoms with the medical 
team (hospital contact 
telephone number XXXXX). 
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Table 1. Overview of scoring algorithm for symptom report and immediate 
patient advice 
 
Algorithm  Summary*  Immediate patient advice 
A1 One or more Level 3 
problem, current - 
contact the hospital now 
You have indicated a serious problem 
in this area. We recommend that you 
contact the hospital now to discuss 
your symptoms with the medical team 
A2 Level 3 problem(s) which 
have improved, contact 
the team when 
convenient 
You have reported that you have been 
experiencing some serious problems 
which have now improved. If you have 
not already been in contact with your 
medical team, we recommend that you 
contact them to discuss your 
symptoms when convenient, or 
mention them at your next clinic 
appointment (if in the next 1-2 weeks). 
If you have already been in touch with 
your medical team regarding your 
symptoms, please follow the advice 
they have given you. 
 
B Three or more Level 2 
medically important 
problems; contact the 
team when convenient 
If your symptoms are new or have 
changed recently, please either 
contact the hospital when convenient 
to discuss your symptoms with the 
medical team or mention them at your 
next clinic appointment (if in the next 1-
2 weeks).  
 
C Mild symptoms, do not 
require medical attention 
at present, self-
management advice 
Follow self-management advice 
D No problems reported No advice 
* Level 3= severe; Level 2= moderate; Level 1= mild 
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Figure 2: eRAPID case study 
 
 
27 
 
 
 
